Susquehanna International Group’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.52M | Sell |
113,665
-8,184
| -7% | -$109K | ﹤0.01% | 2657 |
|
|
2025
Q1 | $1.24M | Sell |
121,849
-89,460
| -42% | -$912K | ﹤0.01% | 2997 |
|
|
2024
Q4 | $3.35M | Buy |
211,309
+202,261
| +2,235% | +$3.2M | ﹤0.01% | 1415 |
|
|
2024
Q3 | $525K | Buy |
9,048
+666
| +8% | +$38.7K | ﹤0.01% | 3587 |
|
|
2024
Q2 | $383K | Sell |
8,382
-7,043
| -46% | -$322K | ﹤0.01% | 3882 |
|
|
2024
Q1 | $1.02M | Sell |
15,425
-107
| -0.7% | -$7.08K | ﹤0.01% | 2619 |
|
|
2023
Q4 | $618K | Buy |
+15,532
| New | +$618K | ﹤0.01% | 3551 |
|
|
2023
Q3 | – | Sell |
-8,770
| Closed | -$352K | – | 5988 |
|
|
2023
Q2 | $352K | Sell |
8,770
-17,783
| -67% | -$715K | ﹤0.01% | 4050 |
|
|
2023
Q1 | $1.13M | Buy |
26,553
+18,546
| +232% | +$792K | ﹤0.01% | 2715 |
|
|
2022
Q4 | $384K | Sell |
8,007
-28,015
| -78% | -$1.35M | ﹤0.01% | 3561 |
|
|
2022
Q3 | $1.36M | Buy |
+36,022
| New | +$1.36M | ﹤0.01% | 2133 |
|
|
2022
Q2 | – | Sell |
-20,045
| Closed | -$1.09M | – | 6282 |
|
|
2022
Q1 | $1.09M | Buy |
20,045
+2,712
| +16% | +$147K | ﹤0.01% | 2698 |
|
|
2021
Q4 | $1.01M | Buy |
17,333
+4,380
| +34% | +$256K | ﹤0.01% | 2852 |
|
|
2021
Q3 | $512K | Buy |
12,953
+4,230
| +48% | +$167K | ﹤0.01% | 3677 |
|
|
2021
Q2 | $370K | Buy |
+8,723
| New | +$370K | ﹤0.01% | 4244 |
|
|
2021
Q1 | – | Sell |
-6,398
| Closed | -$451K | – | 5484 |
|
|
2020
Q4 | $451K | Buy |
+6,398
| New | +$451K | ﹤0.01% | 3513 |
|